[
PET/CT
[18F]-FDHT
androgen receptor
high-grade gliomas
Journal
Neuro-oncology advances
ISSN: 2632-2498
Titre abrégé: Neurooncol Adv
Pays: England
ID NLM: 101755003
Informations de publication
Date de publication:
Historique:
entrez:
19
3
2021
pubmed:
20
3
2021
medline:
20
3
2021
Statut:
epublish
Résumé
G lioblastoma (GBM) is associated with poor overall survival. Recently, we showed that androgen receptor (AR) protein is overexpressed in 56% of GBM specimens and AR antagonists induced dose-dependent death in several GBM cell lines and significantly reduced tumor growth and prolonged the lifespan of mice implanted with human GBM. 16β-18F-fluoro-5α-dihydrotestosterone ([ Twelve patients with suspected high-grade glioma underwent a regular workup and additional dynamic and static [ In six of the 12 patients, [ [
Sections du résumé
BACKGROUND
BACKGROUND
G lioblastoma (GBM) is associated with poor overall survival. Recently, we showed that androgen receptor (AR) protein is overexpressed in 56% of GBM specimens and AR antagonists induced dose-dependent death in several GBM cell lines and significantly reduced tumor growth and prolonged the lifespan of mice implanted with human GBM. 16β-18F-fluoro-5α-dihydrotestosterone ([
METHODS
METHODS
Twelve patients with suspected high-grade glioma underwent a regular workup and additional dynamic and static [
RESULTS
RESULTS
In six of the 12 patients, [
CONCLUSION
CONCLUSIONS
[
Identifiants
pubmed: 33738450
doi: 10.1093/noajnl/vdab019
pii: vdab019
pmc: PMC7954111
doi:
Types de publication
Journal Article
Langues
eng
Pagination
vdab019Informations de copyright
© The Author(s) 2021. Published by Oxford University Press, the Society for Neuro-Oncology and the European Association of Neuro-Oncology.
Références
J Nucl Med. 2017 Dec;58(12):1906-1912
pubmed: 28912144
Adv Biomed Res. 2019 Feb 27;8:18
pubmed: 30993088
J Labelled Comp Radiopharm. 2016 Aug;59(10):424-8
pubmed: 27378195
Clin Nucl Med. 2016 Jun;41(6):e281-7
pubmed: 26673240
Neuro Oncol. 2016 Sep;18(9):1199-208
pubmed: 27106405
World J Mens Health. 2019 Sep;37(3):288-295
pubmed: 30209899
JAMA Oncol. 2017 Sep 1;3(9):1266-1273
pubmed: 28301631
Int J Rad Appl Instrum B. 1988;15(1):53-67
pubmed: 3280523
Clin Cancer Res. 1999 Oct;5(10):2674-81
pubmed: 10537328
J Nucl Med. 1996 Jun;37(6):1009-15
pubmed: 8683293
J Nucl Med. 1984 Nov;25(11):1212-21
pubmed: 6092569
Cancer Treat Rev. 2018 Jul;68:102-110
pubmed: 29940524
Eur J Nucl Med Mol Imaging. 2015 Feb;42(2):328-54
pubmed: 25452219
Eur J Nucl Med Mol Imaging. 2018 May;45(5):886-887
pubmed: 29387926
J Nucl Med. 1992 May;33(5):724-34
pubmed: 1569482
Oncotarget. 2018 Apr 13;9(28):19980-19993
pubmed: 29731997
Cancer. 2000 Jun 15;88(12):2887
pubmed: 10870076
Eur J Nucl Med Mol Imaging. 2005 Mar;32(3):344-50
pubmed: 15726353
EJNMMI Phys. 2020 Jan 14;7(1):4
pubmed: 31938953
J Nucl Med. 2004 Mar;45(3):366-73
pubmed: 15001675
Clin Cancer Res. 1997 Jan;3(1):81-5
pubmed: 9815541
Nat Rev Neurol. 2017 May;13(5):279-289
pubmed: 28387340
Acta Pharmacol Sin. 2015 Jan;36(1):3-23
pubmed: 24909511
Oncology (Williston Park). 2019 Mar 13;33(3):91-100
pubmed: 30866031
Nat Methods. 2012 Jul;9(7):671-5
pubmed: 22930834